XML 33 R22.htm IDEA: XBRL DOCUMENT v3.25.3
SEGMENT INFORMATION
 9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
The Company operates and manages its business as one reportable operating segment which provides multi-cancer early detection testing and services. The Company's chief operating decision maker (“CODM”) is the chief executive officer. The chief operating decision maker reviews financial information on an aggregate basis for the purposes of evaluating financial performance and allocating resources based on net income (loss), adjusted gross margin and adjusted EBITDA. Net income (loss) is the measure of segment profit most consistent with U.S. GAAP that is regularly reviewed by the CODM to allocate resources and assess performance. The CODM does not evaluate operating segment performance using asset information.
The following table is representative of the significant expense categories regularly provided to the CODM when managing the Company’s single reporting segment. A reconciliation to the consolidated net loss for the three and nine months ended September 30, 2025 and September 30, 2024 is included in the table below:

Three Months EndedNine Months Ended
(in thousands)September 30,
2025		September 30,
2024		September 30,
2025		September 30,
2024
Revenue:
Screening revenue$32,807 $25,374 $96,319 $77,076 
Development services revenue3,387 3,278 7,256 10,267 
Total revenue36,194 28,652 103,575 87,343 
Costs and operating expenses:
Cost of screening revenue (exclusive of amortization of intangible assets) (1)(2)
15,910 15,970 52,379 45,481 
Cost of development services revenue (1)(2)
544 1,442 2,216 3,499 
Compensation53,375 84,733 173,537 257,578 
Depreciation and intangible assets amortization expense37,646 38,630 112,577 114,808 
Stock-based compensation13,868 16,871 43,068 70,980 
Professional services8,831 11,298 27,353 52,459 
Cloud computing and information technology6,416 7,517 19,537 23,619 
Clinical studies7,835 8,048 20,020 39,280 
Laboratory supplies and research collaborations3,242 8,556 10,421 37,631 
Facilities5,517 6,185 16,510 21,344 
Other segment expenses (3)
8,301 12,909 35,709 51,948 
Goodwill and intangible assets impairment— — 28,000 1,420,936 
Total costs and operating expenses161,485 212,159 541,327 2,139,563 
Loss from Operations(125,291)(183,507)(437,752)(2,052,220)
Other income (expense):
Interest income6,107 11,661 20,695 17,367 
Other income (expense), net466 (561)(929)(514)
Benefit from income taxes29,741 46,719 108,811 105,428 
Net Loss$(88,977)$(125,688)$(309,175)$(1,929,939)
(1) Cost of screening revenue (exclusive of amortization of intangible assets) and cost of development services revenue include stock-based compensation expense. See Note 8 — Stock-Based Compensation for further details.
(2) Cost of screening revenue (exclusive of amortization of intangible assets) and cost of development services revenue include $1.3 million and $4.9 million of depreciation expense for the three and nine months ended September 30, 2025 and $0.6 million and $3.8 million for the three and nine months ended September 30, 2024.
(3) Other segment expenses primarily includes costs related to contractors and temporary labor, marketing expenses, legal expenses, and credit loss expense